Ranpirnase

Identification

Name
Ranpirnase
Accession Number
DB04950
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Other protein based therapies
Description

Ranpirnase is a ribonuclease enzyme found in Rana pipiens oocytes. It is being studied in the treatment of cancer. It is manufactured by Alfacell Corporation. It is the first ribonuclease to enter cancer clinical trials.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
International/Other Brands
Onconase
Categories
UNII
ZE15FIT23E
CAS number
196488-72-9

Pharmacology

Indication

For the treatment of various forms of cancer.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action

Ranpirnase controls tumour growth by degrading RNA within cancer cells, resulting in inhibition of protein synthesis and arresting mitosis in G(1)phase.

TargetActionsOrganism
UDNANot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Ranpirnase.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Ranpirnase.Experimental
BevacizumabBevacizumab may increase the cardiotoxic activities of Ranpirnase.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ranpirnase.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Ranpirnase.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Ranpirnase.Experimental
DeslanosideDeslanoside may decrease the cardiotoxic activities of Ranpirnase.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Ranpirnase.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Ranpirnase.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Ranpirnase.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ranpirnase.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Ranpirnase.Experimental
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Ranpirnase.Experimental
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Ranpirnase.Experimental
OleandrinOleandrin may decrease the cardiotoxic activities of Ranpirnase.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Ranpirnase.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ranpirnase.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Ranpirnase.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Ranpirnase.Experimental
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Ranpirnase.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Vogelzang NJ, Aklilu M, Stadler WM, Dumas MC, Mikulski SM: A phase II trial of weekly intravenous ranpirnase (Onconase), a novel ribonuclease in patients with metastatic kidney cancer. Invest New Drugs. 2001;19(3):255-60. [PubMed:11561684]
  2. Pavlakis N, Vogelzang NJ: Ranpirnase--an antitumour ribonuclease: its potential role in malignant mesothelioma. Expert Opin Biol Ther. 2006 Apr;6(4):391-9. [PubMed:16548765]
  3. Authors unspecified: Ranpirnase: amphibian ribonuclease A, P-30 protein-alfacell. Drugs R D. 2007;8(2):120-4. [PubMed:17324010]
  4. Lee I, Kalota A, Gewirtz AM, Shogen K: Antitumor efficacy of the cytotoxic RNase, ranpirnase, on A549 human lung cancer xenografts of nude mice. Anticancer Res. 2007 Jan-Feb;27(1A):299-307. [PubMed:17352247]
  5. Lee I, Kim DH, Sunar U, Magnitsky S, Shogen K: The therapeutic mechanisms of ranpirnase-induced enhancement of radiation response on A549 human lung cancer. In Vivo. 2007 Sep-Oct;21(5):721-8. [PubMed:18019404]
  6. Suhasini AN, Sirdeshmukh R: Transfer RNA cleavages by onconase reveal unusual cleavage sites. J Biol Chem. 2006 May 5;281(18):12201-9. Epub 2006 Feb 23. [PubMed:16497678]
  7. Link [Link]
External Links
PubChem Substance
347909856
Wikipedia
Ranpirnase

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2CompletedTreatmentCondylomata Acuminata / Papillomavirus Infections / Sexually Transmitted Disease (STD)1
2WithdrawnTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
3Unknown StatusTreatmentMesothelioma, Malignant1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

1. DNA
Kind
Nucleotide
Organism
Human
Pharmacological action
Unknown
General Function:
Used for biological information storage.
Specific Function:
DNA contains the instructions needed for an organism to develop, survive and reproduce.
Molecular Weight:
2.15 x 1012 Da
References
  1. Authors unspecified: Ranpirnase: amphibian ribonuclease A, P-30 protein-alfacell. Drugs R D. 2007;8(2):120-4. [PubMed:17324010]

Drug created on October 21, 2007 16:23 / Updated on November 06, 2017 06:45